Recursion Pharmaceuticals
PublicRecursion Pharmaceuticals is now publicly traded
The data on this page reflects Recursion Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 16, 2021
Last Round
Follow-on Offering
Jun 26, 2024
Est. Valuation at Exit
$1.74B
Total Funding Raised
$1.14B
Company Overview
Recursion Pharmaceuticals is a biotechnology company that industrializes drug discovery by integrating technological innovations across biology, chemistry, automation, data science, and engineering.
Sector
Biotech
AI Layer
Infrastructure
Keywords
Recursion Pharmaceuticals Comparables
Compare Recursion Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 87% | |
| Insilico Medicine | 87% | |
| Insitro | 86% | |
Recursion Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jun 26, 2024 | ||||
| IPO | Apr 16, 2021 | ||||
| Series D | Sep 9, 2020 | ||||
| Series C | Jul 15, 2019 | ||||
| Series B | Oct 4, 2017 | ||||
Series A | Oct 3, 2016 |
Recursion Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Scottish Mortgage Investment Trust | Series C |
| Advantage Capital | Series D, Series B |
| Intermountain Ventures | Series D, Series C |
| Lux Capital | Series D, Series C, Series B, Series A |
| Catalio Capital Management | Series D |
| Obvious Ventures | Series D, Series C, Series A, Series B |
| Wild Basin Investments | Series A |
Recursion Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
